Skip to main content
Erschienen in: Diabetology International 3/2021

02.01.2021 | Original Article

Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression-

verfasst von: Tatsuo Yanagawa, Keiko Koyano, Koichiro Azuma

Erschienen in: Diabetology International | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Aim

This study was aimed at retrospectively investigating some common clinical factors, including the serum level of magnesium (Mg), associated with progression and remission/regression of diabetic kidney disease (DKD).

Methods

The subjects were 690 Japanese patients with type 2 diabetes mellitus who were receiving treatment with oral antidiabetic drugs other than SGLT2 inhibitors. Routine clinical data were collected on the first and last day of the observation period. The prognosis of DKD is categorized into four stages according to the Kidney Disease Improving Global Outcomes classification. Progression was defined as transition from any of the lower three risk categories (LR, MIR, HR) at the start of the observation period, to the VHR stage/category at the end of the observation period. Remission/regression was defined as improvement of the risk category by at least one stage from the start to the end of the observation period. Factors associated with progression and regression/remission were investigated using Cox proportional hazards analysis. Furthermore, the factors associated with the annual decrease in eGFR of 5 ml/min/1.73 m2 or more were examined by logistic regression analysis. Factors associated with transition of urinary protein negative to trace or positive, or transition of negative or trace to positive, were investigated by Cox proportional hazard analysis.

Results

The observation period was 2251 ± 1614 days. Age (Exp [B] = 1.10, 95% CI; 1.06–1.14; P < 0.01; 1 year old), serum Mg (Exp [B] = 0.82, 95% CI; 0.71–0.95; P < 0.01); 0.1 mg/dl), and serum HbA1c (Exp [B] = 1.03, 95% CI; 1.01–1.05; P < 0.01: 0.1%) were associated with progression of DKD; on the other hand, serum ALT was associated with the likelihood of remission/regression of DKD (Exp [B] = 1.01, 95% CI; 1.002–1.018; P < 0.05; 1 IU/L). The decline in eGFR was associated with higher HbA1c levels, hypomagnesemia, and lower ALT. The new appearance of trace or overt proteinuria was correlated with higher HbA1c levels, advancing age, hypomagnesemia and hypertriglycemia.

Conclusion

Our findings confirmed previous reports that advancing age and serum HbA1c levels were associated with an increased risk of progression of DKD. Lower serum Mg concentrations were also found to be associated with a high risk of progression of DKD, and interventional studies are needed to confirm a causal relationship. Elevated HbA1c levels and hypomagnesemia were common factors in the decline in eGFR and the appearance of trace or overt proteinuria. Lower serum ALT levels were associated with the decline in eGFR. Since serum ALT is known to decrease as the renal function deteriorates, serum ALT is considered to be a marker of renal function.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Goto A, Noda M, Inoue M, Goto M, Charvat H. Increasing number of people with diabetes in Japan: is this trend real? Intern Med. 2016;55:1827–30.CrossRef Goto A, Noda M, Inoue M, Goto M, Charvat H. Increasing number of people with diabetes in Japan: is this trend real? Intern Med. 2016;55:1827–30.CrossRef
2.
Zurück zum Zitat Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3–7.CrossRef Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3–7.CrossRef
3.
Zurück zum Zitat Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.CrossRef Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.CrossRef
4.
Zurück zum Zitat Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol. 2011;6:2444–51.CrossRef Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol. 2011;6:2444–51.CrossRef
5.
Zurück zum Zitat Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, et al. Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes. Clin J Am Soc Nephrol. 2019;14:862–72.CrossRef Ohkuma T, Jun M, Chalmers J, Cooper ME, Hamet P, Harrap S, et al. Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes. Clin J Am Soc Nephrol. 2019;14:862–72.CrossRef
6.
Zurück zum Zitat Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Chapter 1: Definition and classification of CKD. Kidney Int. 2013;3:5–62.CrossRef Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease Chapter 1: Definition and classification of CKD. Kidney Int. 2013;3:5–62.CrossRef
7.
Zurück zum Zitat Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8:6–18.CrossRef Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8:6–18.CrossRef
8.
Zurück zum Zitat Oliveira B, Cunningham J, Walsh SB. Magnesium balance in chronic and end-stage kidney disease. Adv Chronic Kidney Dis. 2018;25:291–5.CrossRef Oliveira B, Cunningham J, Walsh SB. Magnesium balance in chronic and end-stage kidney disease. Adv Chronic Kidney Dis. 2018;25:291–5.CrossRef
9.
Zurück zum Zitat Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, et al. Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87:820–7.CrossRef Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, et al. Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87:820–7.CrossRef
10.
Zurück zum Zitat Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005;63:429–36.CrossRef Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005;63:429–36.CrossRef
11.
Zurück zum Zitat Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35:1591–7.CrossRef Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35:1591–7.CrossRef
12.
Zurück zum Zitat Hovind P, Tarnow L, Parving HH. Remission and regression of diabetic nephropathy. Curr Hypertens Rep. 2004;6:377–82.CrossRef Hovind P, Tarnow L, Parving HH. Remission and regression of diabetic nephropathy. Curr Hypertens Rep. 2004;6:377–82.CrossRef
13.
Zurück zum Zitat Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19:2784–8.CrossRef Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19:2784–8.CrossRef
14.
Zurück zum Zitat Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int. 2019;95:178–87.CrossRef Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int. 2019;95:178–87.CrossRef
15.
Zurück zum Zitat Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–54.CrossRef Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–54.CrossRef
16.
Zurück zum Zitat American Diabetes Association 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):S14–31.CrossRef American Diabetes Association 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1):S14–31.CrossRef
17.
Zurück zum Zitat Miyazaki H, Babazono A, Nishi T, Maeda T, Imatoh T, Ichiba M, et al. Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease? BMC Pharmacol Toxicol. 2015;16:22.CrossRef Miyazaki H, Babazono A, Nishi T, Maeda T, Imatoh T, Ichiba M, et al. Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease? BMC Pharmacol Toxicol. 2015;16:22.CrossRef
18.
Zurück zum Zitat Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
19.
Zurück zum Zitat Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91:1300–11.CrossRef Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91:1300–11.CrossRef
20.
Zurück zum Zitat Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.CrossRef Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.CrossRef
21.
Zurück zum Zitat Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23:19–28.CrossRef Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23:19–28.CrossRef
22.
Zurück zum Zitat Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.CrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.CrossRef
23.
Zurück zum Zitat Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, et al. Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience. J Investig Med. 2019;67:987–94.CrossRef Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, et al. Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience. J Investig Med. 2019;67:987–94.CrossRef
24.
Zurück zum Zitat Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160–73.CrossRef Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160–73.CrossRef
25.
Zurück zum Zitat Rebholz CM, Tin A, Liu Y, Kuczmarski MF, Evans MK, Zonderman AB, Crews DC. Dietary magnesium and kidney function decline: the healthy aging in neighborhoods of diversity across the life span study. Am J Nephrol. 2016;44:381–7.CrossRef Rebholz CM, Tin A, Liu Y, Kuczmarski MF, Evans MK, Zonderman AB, Crews DC. Dietary magnesium and kidney function decline: the healthy aging in neighborhoods of diversity across the life span study. Am J Nephrol. 2016;44:381–7.CrossRef
26.
Zurück zum Zitat Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7:8199–226.CrossRef Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7:8199–226.CrossRef
27.
Zurück zum Zitat Hata A, Doi Y, Ninomiya T, Mukai N, Hirakawa Y, Hata J, et al. Magnesium intake decreases Type 2 diabetes risk through the improvement of insulin resistance and inflammation: the Hisayama Study. Diabet Med. 2013;30:1487–94.CrossRef Hata A, Doi Y, Ninomiya T, Mukai N, Hirakawa Y, Hata J, et al. Magnesium intake decreases Type 2 diabetes risk through the improvement of insulin resistance and inflammation: the Hisayama Study. Diabet Med. 2013;30:1487–94.CrossRef
28.
Zurück zum Zitat Qu X. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS ONE. 2013;8:e57720.CrossRef Qu X. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS ONE. 2013;8:e57720.CrossRef
29.
Zurück zum Zitat Dong JF, Cruz MA, Aboulfatova K, Martin C, Choi H, Bergeron AL, et al. Magnesium maintains endothelial integrity, upregulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost. 2008;99:586–93.CrossRef Dong JF, Cruz MA, Aboulfatova K, Martin C, Choi H, Bergeron AL, et al. Magnesium maintains endothelial integrity, upregulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost. 2008;99:586–93.CrossRef
30.
Zurück zum Zitat Vervloet M. Modifying phosphate toxicity in chronic kidney disease. Toxins (Basel). 2019;11:522.CrossRef Vervloet M. Modifying phosphate toxicity in chronic kidney disease. Toxins (Basel). 2019;11:522.CrossRef
31.
Zurück zum Zitat Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, et al. A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol. 2019;30:1073–85.CrossRef Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, et al. A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol. 2019;30:1073–85.CrossRef
32.
Zurück zum Zitat Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696–703.CrossRef Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696–703.CrossRef
33.
Zurück zum Zitat Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, et al. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. PLoS ONE. 2015;10:e0142808.CrossRef Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, et al. Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus. PLoS ONE. 2015;10:e0142808.CrossRef
34.
Zurück zum Zitat Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract. 2014;4:847539. Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract. 2014;4:847539.
35.
Zurück zum Zitat Adiga US, Malawadi BN. Association of diabetic nephropathy and liver disorders. J Clin Diagn Res. 2016;10:BC05–7.PubMedPubMedCentral Adiga US, Malawadi BN. Association of diabetic nephropathy and liver disorders. J Clin Diagn Res. 2016;10:BC05–7.PubMedPubMedCentral
36.
Zurück zum Zitat Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges. Int J Appl Basic Med Res. 2015;5:31–5.CrossRef Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges. Int J Appl Basic Med Res. 2015;5:31–5.CrossRef
37.
Zurück zum Zitat Candinas D, Keusch G, Schlumpf R, Burger HR, Gmür J, Largiadèr F. Hemolytic-uremic syndrome following kidney transplantation: prognostic factors. Schweiz Med Wochenschr. 1994;124:1789–99.PubMed Candinas D, Keusch G, Schlumpf R, Burger HR, Gmür J, Largiadèr F. Hemolytic-uremic syndrome following kidney transplantation: prognostic factors. Schweiz Med Wochenschr. 1994;124:1789–99.PubMed
38.
Zurück zum Zitat Ruhl CE, Everhart JE. The association of low serum alanine aminotransferase activity with mortality in the US population. Am J Epidemiol. 2013;178:1702–11.CrossRef Ruhl CE, Everhart JE. The association of low serum alanine aminotransferase activity with mortality in the US population. Am J Epidemiol. 2013;178:1702–11.CrossRef
Metadaten
Titel
Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression-
verfasst von
Tatsuo Yanagawa
Keiko Koyano
Koichiro Azuma
Publikationsdatum
02.01.2021
Verlag
Springer Singapore
Erschienen in
Diabetology International / Ausgabe 3/2021
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-020-00483-1

Weitere Artikel der Ausgabe 3/2021

Diabetology International 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.